DUBAI, UAE, March 14, 2012 /PRNewswire/ --
- United Arab Emirates is the First Country in the Middle East to Introduce Omnaris® to Region's Allergy Sufferers -
Nycomed, a Takeda company, today announced that Omnaris® (ciclesonide) Nasal Spray is now available in the United Arab Emirates for the treatment of allergic rhinitis, also known as nasal allergies and hay fever, in adults and adolescents over the age of 12.
Omnaris® Nasal Spray is a long-lasting therapy indicated for the treatment of seasonal allergic rhinitis (SAR) nasal symptoms in adults and adolescents 12 years of age and older, and for perennial allergic rhinitis (PAR) nasal symptoms in adults and adolescents 12 years of age and older. Omnaris® is a corticosteroid with a unique pro-drug formulation that has been shown to be highly tolerable and able to provide fast and powerful relief from bothersome nasal symptoms.
The symptoms associated with allergic rhinitis, such as nasal congestion and runny nose, can be bothersome enough to interfere with work and school productivity and diminish quality of life. Nasal allergies are generally recognized as the most common chronic respiratory disorder worldwide with approximately 400 million people affected.
More than one third of adults across the Emirates suffer from allergic rhinitis. With prevalence rates in the Middle East currently estimated to be as high as 10 per cent and rising, the socioeconomic burden of nasal allergies is significant.
"The Allergies in the Middle East Survey highlights an unmet need for a safe, effective, fast and long-lasting allergy treatment for adults and adolescents in the Middle East where more and more people are suffering from allergic rhinitis," said Dr. Hussain Abdul Rahman, MSc. Director of Medical Affairs, Consultant and Head of ENT Departmen
Copyright©2010 PR Newswire.
All rights reserved